HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Felice, K. J. Articles by Mathews, K. D. Search for Related Content PubMed PubMed Citation Articles by Felice, K. J. Articles by Mathews, K. D.

FSH dystrophy 4q35 deletion in patients presenting with facial-sparing scapular myopathy

From the Department of Neurology (Drs. Felice and North), University of Connecticut School of Medicine, Farmington; and the Departments of Pathology (Dr. Moore) and Pediatrics (Dr. Mathews), University of Iowa College of Medicine, Iowa City.

Address correspondence and reprint requests to Dr. Kevin J. Felice, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1840.

OBJECTIVE: To evaluate the incidence of the facioscapulohumeral dystrophy (FSHD) 4q35 deletion in patients with facial-sparing scapular myopathy.

BACKGROUND: Scapular winging is typical of FSHD but may also be prominent in other muscle disorders including scapuloperoneal syndromes. With DNA testing, it is possible to determine if patients with facial-sparing scapular myopathy have FSHD.

METHODS: Fourteen of 17 unrelated patients with facial-sparing scapular myopathy, seen over a 7-year period at a regional neuromuscular center, agreed to have DNA testing for FSHD. The clinical and laboratory features of these patients were also noted.

RESULTS: Of the 14 patients, 10 (71%) had restriction fragments consistent with the 4q35 deletion. The mean size of the smaller fragment following EcoRI digestion was 29.5 kb (range 20 to 39). The mean age at onset was 19.9 years; at presentation, 44.7 years. Except for the absence of facial weakness, most patients had clinical and laboratory features otherwise consistent with FSHD. Five patients (50%) had a positive family history of similar weakness. Following removal of outliers, the Pearson correlation coefficient (r) value between EcoRI fragment size and age at onset was 0.64, and between fragment size and limb muscle strength, 0.64.

CONCLUSION: The FSHD 4q35 deletion was found in 71% of the facial-sparing scapular myopathy patients. They otherwise resemble typical FSHD patients in age at onset, physical characteristics, and association between fragment size and disease severity.

Key words: Facioscapulohumeral muscular dystrophy—Scapular myopathy—Scapular winging—Inherited muscle disease—Muscular dystrophy—Scapuloperoneal dystrophy.

This article has been cited by other articles:

				M. Krasnianski, K. Eger, S. Neudecker, S. Jakubiczka, and S. Zierz Atypical Phenotypes in Patients With Facioscapulohumeral Muscular Dystrophy 4q35 Deletion Arch Neurol, October 1, 2003; 60(10): 1421 - 1425. [Abstract] [Full Text] [PDF]

				R. J.L.F. Lemmers, M. Osborn, T. Haaf, M. Rogers, R. R. Frants, G. W. Padberg, D. N. Cooper, S. M. van der Maarel, and M. Upadhyaya D4F104S1 deletion in facioscapulohumeral muscular dystrophy: Phenotype, size, and detection Neurology, July 22, 2003; 61(2): 178 - 183. [Abstract] [Full Text] [PDF]